Journal of Clinical Oncology

Genome-Wide Association Study Identifies ROBO2 as a Novel Susceptibility Gene for Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors..  41:1758-1769. 2023

Financial Burden in Blood or Marrow Transplantation Survivors During the COVID-19 Pandemic: A BMTSS Report.  41:1011-1022. 2023

Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors.  41:1046-1058. 2023

Racial and Ethnic Disparities in Cervical Cancer Incidence, Survival, and Mortality by Histologic Subtype.  41:1059-1068. 2023

Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer..  JCO2202423. 2023

Symptom Clusters in Childhood Cancer Survivors.  41:439-442. 2023

Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease..  JCO2201203. 2023

Cost-Effectiveness of Pharmacologic Treatment Options for Women with Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer.  41:32-42. 2023

Associations between insurance status and the cancer clinical trial enrollment process..  40:85-85. 2022

Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated with Blood or Marrow Transplantation: The Results of the BMT Survivor Study.  40:3278-3288. 2022

Interest and enrollment in clinical trials by race and ethnicity, rurality, and insurance status in patients with ovarian cancer..  40:83-83. 2022

Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.  40:3205-3221. 2022

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.  40:2901-2912. 2022

Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3 /ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031.  40:2023-2035. 2022

Trends in Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplantation Over Three Decades: A BMTSS Report.  40:1991-2003. 2022

Clinical outcomes in COVID-19 patients with cancer who are treated with chemo- or immunotherapy..  40:e18699-e18699. 2022

Neoadjuvant modified FOLFIRINOX or gemcitabine-nab paclitaxel followed by stereotactic body radiotherapy (SBRT) for patients with locally advanced pancreatic cancer and borderline pancreatic inoperable cancers..  40:e16253-e16253. 2022

Reducing regorafenib toxicity by combining with dual JAK-HDAC inhibitor in colorectal cancer..  40:e15597-e15597. 2022

Survival outcomes of patients with relapsed or refractory acute myeloid leukemia after venetoclax combined with hypomethylating agents..  40:e18808-e18808. 2022

Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients with Myelofibrosis with Progression or Suboptimal Response: Phase II Safety and Efficacy.  40:1671-1680. 2022

SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.  40:1574-1582. 2022

Exercise, Diet, and Weight Management during Cancer Treatment: ASCO Guideline.  348. 2022

Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement.  111. 2022

Radioactive Iodine: Recognizing the Need for Risk-Benefit Balance.  40:1396-1399. 2022

Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative.  40:1414-1427. 2022

Disease Modification in Myelofibrosis: An Elusive Goal?.  40:1147-1154. 2022

Reply to P. Petranović Ovčariček et al.  40. 2022

Reply to K. Takada et al.  39:3997-3998. 2021

Pathway to Precision Patient-Reported Outcomes.  39:3770-3772. 2021

SARS-CoV-2 in Childhood Cancer in 2020: A Disease of Disparities.  39:3778-3788. 2021

Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes.  39:3737-3746. 2021

Physiologic Frailty and Neurocognitive Decline Among Young-Adult Childhood Cancer Survivors: A Prospective Study From the St Jude Lifetime Cohort.  39:3485-3495. 2021

Association of fear of COVID-19 with delays in care or treatment interruptions in patients with cancer..  39:98-98. 2021

Perceptions of barriers to patient financial hardship screening differ by provider role within gynecologic oncology outpatient care..  39:317-317. 2021

System-wide depression screening implementation in ambulatory oncology care: Key strategies and early implementation outcomes..  39:260-260. 2021

Outcomes of COVID-19 in Patients With Cancer: Report From the National COVID Cohort Collaborative (N3C).  39:2232-2246. 2021

Sarcopenia in the Older Adult With Cancer.  39:2068-2078. 2021

Targeted Therapies in Older Adults With Solid Tumors.  39:2128-2137. 2021

A randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition in metastatic soft tissue sarcoma..  39:tps11583-tps11583. 2021

Phase II trial of pegylated arginine deiminase in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma..  39:11508-11508. 2021

Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children’s Oncology Group Trial AALL0331.  39:1540-1553. 2021

Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932.  39:1437-1447. 2021

Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma.  39:1119-1128. 2021

NF106: A neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas.  39:797-806. 2021

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.  38:4274-4282. 2020

Updated breast cancer surveillance recommendations for female survivors of childhood, adolescent, and young adult cancer from the international guideline harmonization group.  38:4194-4207. 2020

Survival in Patients with Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient.  38:3773-3784. 2020

Employment concerns experienced by ovarian cancer patients and caregivers..  38:69-69. 2020

Exploring the three domains of financial hardship experienced by ovarian cancer patients..  38:71-71. 2020

Ovarian cancer patients’ perspectives on facilitators and barriers to accessing financial assistance..  38:64-64. 2020

Children's oncology group AALL0434: A phase III randomized clinical trial testing nelarabine in newly diagnosed t-cell acute lymphoblastic leukemia.  38:3282-3293. 2020

Chronic comorbidities among survivors of adolescent and young adult cancer.  38:3161-3174. 2020

Impact of intrathecal triple therapy versus intrathecal methotrexate on disease-free survival for high-risk B-lymphoblastic leukemia: Children⇔s Oncology Group Study AALL1131.  38:2628-2638. 2020

Genome Wide Association Study (GWAS) of cognitive impairment after blood or marrow transplantation (BMT) for hematologic malignancy..  38:1536-1536. 2020

Clinical and genetic risk prediction of cognitive impairment after blood or marrow transplantation for hematologic malignancy.  38:1312-1321. 2020

Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): A randomized phase III trial.  38:1164-1174. 2020

Clinical Cancer Advances 2020: Annual report on progress against cancer from the American Society of Clinical oncology.  38:1081-1101. 2020

MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2–positive and/or hormone receptor–negative breast cancers in the I-SPY 2 trial.  38:1059-1069. 2020

Forging a new frontier: Providing palliative care to people with cancer in rural and remote areas.  38:963-973. 2020

Outcome in children with standard-risk b-cell acute lymphoblastic leukemia: Results of children's oncology group trial aall0331.  38:602-612. 2020

Prevalence and Predictors of Frailty in Childhood Cancer Survivors and Siblings: A Report From the Childhood Cancer Survivor Study.  38:232-247. 2020

Patient-level factors associated with lack of health care provider recommendation for the human papillomavirus vaccine among young cancer survivors.  38:2892-2901. 2020

Total body irradiation and risk of breast cancer after blood or marrow transplantation: A blood or marrow transplantation survivor study report.  38:2872-2882. 2020

Evaluating the early impact of adding a financial counselor to an Oncology Care Model pilot program..  37:67-67. 2019

Evaluating uptake and patient satisfaction with an out-of-pocket cost tracker for gynecologic cancer patients undergoing treatment..  37:101-101. 2019

The impact of depression in cancer patients on healthcare utilization..  37:243-243. 2019

Utilizing visualization to qualitatively evaluate electronic health record-derived database limitations..  37:317-317. 2019

Visualizing treatment patterns and survival in metastatic breast cancer..  37:316-316. 2019

Clofarabine can replace anthracyclines and etoposide in remission induction therapy for childhood acute myeloid leukemia: The AML08 multicenter, randomized phase III trial.  37:2072-2081. 2019

Impact of travel time on health care costs and resource use by phase of care for older patients with cancer.  37:1935-1945. 2019

A novel association between GSTM1 null variant and anthracycline-induced cardiac dysfunction (ACD) in childhood cancer survivors (CCS): A COG ALTE03N1 report..  37:10030-10030. 2019

Candidate SNPs enhance prediction of cognitive impairment after blood or marrow transplantation (BMT) for hematologic malignancy (HM)..  37:11520-11520. 2019

Risk prediction of anthracycline-related cardiomyopathy (AC) in childhood cancer survivors (CCS): A COG-ALTE03N1 and CCSS report..  37:10015-10015. 2019

Validation of MSKCC pre-prostatectomy nomogram in men who undergo MRI-targeted prostate biopsy prior to radical prostatectomy..  37:14-14. 2019

Bridging the data-free zone: Decision making for older adults with cancer.  37:3469-3472. 2019

Hematopoietic stem-cell transplantation does not improve the poor outcome of children with hypodiploid acute lymphoblastic leukemia: A report from children's oncology group.  37:780-789. 2019

Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16.  37:3377-3391. 2019

Multicenter, prospective, phase II and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma.  37:3446-3454. 2019

Subsequent breast cancer in female childhood cancer survivors in the St Jude Lifetime Cohort Study (SJLIFE).  37:1647-1656. 2019

Subsequent neoplasms after a primary tumor in individuals with neurofibromatosis type 1.  37:3050-3058. 2019

Survival by race and ethnicity in pediatric and adolescent patients with hodgkin lymphoma: A children’s oncology group study.  37:3009-3017. 2019

Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era.  37:471-480. 2019

End-of-life care intensity in patients undergoing allogeneic hematopoietic cell transplantation: A population-level analysis.  36:3023-3030. 2018

Should we be talking about guidelines with patients? A qualitative analysis in metastatic breast cancer..  36:217-217. 2018

Trust but verify: Patterns of obtaining health information and the role of physician trust in decision-making amongst patients with metastatic breast cancer..  36:218-218. 2018

Improved survival for children and young adults with t-lineage acute lymphoblastic leukemia: Results from the children's oncology Group AALL0434 methotrexate randomization.  36:2926-2934. 2018

Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with philadelphia chromosome–positive acute lymphoblastic leukemia: Results of children’s oncology group trial AALL0622.  36:2306-2313. 2018

Peripheral neuropathy, sensory processing, and balance in survivors of acute lymphoblastic leukemia.  36:2315-2322. 2018

Surveillance for late effects in childhood cancer survivors.  36:2216-2222. 2018

Reply to E. Parkin et al.  36:2133-2134. 2018

Antibiotic use and overall survival in lung cancer patients receiving nivolumab..  36:e15109-e15109. 2018

East Carolina University clinical experience study: Utilization of liquid biopsy to determine time to diagnosis and treatment in non-small cell lung cancer (NSCLC)..  36:e18519-e18519. 2018

Outcomes of immunomodulatory radiation strategies in combination with nivolumab compared with single agent nivolumab in lung cancer patients..  36:e21134-e21134. 2018

Post- progression treatment patterns in advanced lung cancer patients treated with nivolumab..  36:e21070-e21070. 2018

Preliminary report of a multicenter, phase 2 study of bevacizumab in children and adults with neurofibromatosis 2 and progressive vestibular schwannomas: An NF Clinical Trials Consortium study..  36:2056-2056. 2018

New-onset cardiovascular morbidity in older adults with stage i to III colorectal cancer.  36:609-616. 2018

Phase II trial of carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following androgen pathway inhibitors..  36:224-224. 2018

TP53 germline variations influence the predisposition and prognosis of b-cell acute lymphoblastic leukemia in children.  36:591-599. 2018

Cognitive functioning after hematopoietic cell transplantation for hematologic malignancy: Results from a prospective longitudinal study.  36:463-475. 2018

What is the role of symptom management and patient-reported outcomes in adherence to aromatase inhibitors?.  36:308-309. 2018

Effects of aerobic and resistance exercise on metabolic syndrome, sarcopenic obesity, and circulating biomarkers in overweight or obese survivors of breast cancer: A randomized controlled trial.  36:875-883. 2018

Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma.  36:859-866. 2018

Development and validation of nomograms predictive of overall and progression-free survival in patients with oropharyngeal cancer.  35:4057-4065. 2017

Prevalence and predictors of sperm banking in adolescents newly diagnosed with cancer: Examination of adolescent, parent, and provider factors influencing fertility preservation outcomes.  35:3830-3836. 2017

Clinical and genetic risk prediction of subsequent CNS tumors in survivors of childhood cancer: A report fromthe COG ALTE03N1 study.  35:3688-3696. 2017

Factors associated with participating in formal support services among family caregivers of older adults with poor-prognosis cancers..  35:21-21. 2017

Geriatric syndromes and association with distress in older cancer patients..  35:189-189. 2017

Human papillomavirus vaccination rates in young cancer survivors.  35:3582-3590. 2017

Arsenic trioxide consolidation allows anthracycline dose reduction for pediatric patients with acute promyelocytic leukemia: Report from the children’s oncology group phase III historically controlled trial AAML0631.  35:3021-3029. 2017

Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: north American intergroup study swog s1117.  35:2745-2753. 2017

Impact of initial CSF findings on outcome among patients with National Cancer Institute standard- and high-risk B-cell acute lymphoblastic leukemia: A report from the Children’s Oncology Group.  35:2527-2534. 2017

Incidence and impact of thromboembolic events in lung cancer patients treated with nivolumab..  35:e20624-e20624. 2017

Mercaptopurine ingestion habits, red cell thioguanine nucleotide levels, and relapse risk in children with acute Lymphoblastic Leukemia: A report from the children’s Oncology group study AALL03N1.  35:1730-1736. 2017

Sequence of stereotactic ablative radiotherapy and immune checkpoint blockade in the treatment of metastatic lung cancer..  35:e20665-e20665. 2017

Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma.  35:1598-1605. 2017

High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.  35:394-401. 2017

Outcomes of ERCC1 high locally advanced esophageal cancer patients treated with non-platinum vs platinum based CRT..  35:192-192. 2017

Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: A secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial.  35:56-62. 2017

Phase I study of selinexor, a selective inhibitor of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or refractory acute leukemia.  34:4094-4101. 2016

Comprehensive geriatric assessment-guided therapy does improve outcomes of older patients with advanced lung cancer.  34:4047-4048. 2016

Differences between women’s preferred and actual experience with ‘shared decision-making’: A mixed method study..  34:34-34. 2016

Differences in self-care behaviors by varying levels of caregiving intensity, performance, and well-being among family caregivers of patients with high-mortality cancer..  34:239-239. 2016

What’s in the ‘special sauce’ of protocol-driven outpatient palliative care consultations?.  34:139-139. 2016

Recommendations for premature ovarian insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup consortium.  34:3440-3450. 2016

Changes in clinical context for Kaposi's sarcoma and non-Hodgkin lymphoma among people with HIV infection in the United States.  34:3276-3283. 2016

Reply to F. Felix et al and M.F. Fay et al.  34:3107-3108. 2016

Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: A retrospective multicohort analysis.  34:2468-2477. 2016

Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: A report from children's oncology group study AALL0232.  34:2380-2388. 2016

Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.  34:2359-2365. 2016

Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome.  34:1864-1871. 2016

Comparison of eight commonly used regimens as first-line treatment of metastatic non-small lung cancer..  34:e20661-e20661. 2016

Multiplatform comprehensive kinase analysis of muscle-invasive bladder cancer (MIBC) to identify potentially actionable therapeutic targets..  34:e16014-e16014. 2016

Patient preference-weighted assessments using the ASCO value framework in recurrent, platinum-sensitive ovarian cancer..  34:6630-6630. 2016

Predictive model for response to first-line treatment for metastatic non-small cell lung cancer..  34:e20657-e20657. 2016

Cardiovascular disease risk profiles in survivors of adolescent and young adult (AYA) cancer: The kaiser permanente AYA cancer survivors study.  34:1626-1633. 2016

Racial/ethnic differences in adverse outcomes among childhood cancer survivors: The childhood cancer survivor study.  34:1634-1643. 2016

Association of Human Papillomavirus and p16 Status with Outcomes in the IMCL-9815 Phase III Registration Trial for Patients with Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated with Radiotherapy with or Without Cetuximab.  34:1300-1308. 2016

Cardiovascular disease among survivors of adult-onset cancer: A community-based retrospective cohort study.  34:1122-1130. 2016

Final Results of the Sunbelt Melanoma trial: A multi-institutional prospective randomized phase III study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy.  34:1079-1086. 2016

Reply to W. Hryniuk et al.  34:1153. 2016

Breast cancer risk in childhood cancer survivors without a history of chest radiotherapy: A report from the childhood cancer survivor study.  34:910-918. 2016

CELF4 variant and anthracycline-related cardiomyopathy: A children's oncology group genome-wide association study.  34:863-870. 2016

Chemotherapy for muscle-invasive bladder cancer: Better late than never?.  34:780-785. 2016

Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma.  34:731-739. 2016

A right atrial mass: "more than meets the eye".  34:e49-e50. 2016

Pattern of CA19-9 response to neoadjuvant chemotherapy in locally advanced, borderline resectable pancreatic cancer to predict progression..  34:321-321. 2016

Changes in biomarkers and DNA methylation in breast cancer survivors enrolled in the ENERGY weight loss trial: A pilot study..  34:181. 2016

Evaluation of patient characteristics that are associated with response to a survivorship care planning intervention..  34:8-8. 2016

Physical activity communication between oncology providers and patients with early stage breast, colon or prostate cancer..  34:171-171. 2016

Association of a combined panel of tumor infiltrating lymphocytes, plasma cells, and macrophages with recurrence of localized clear cell (cc) renal cell carcinoma (RCC) undergoing surgery..  34:502-502. 2016

The prevalence of objectively measurable disease in phase III trials of metastatic castration-resistant prostate cancer (mCRPC)..  34:215-215. 2016

Vascular tumor burden as a new quantitative CT imaging biomarker for predicting metastatic RCC response to antiangiogenic therapy..  34:595-595. 2016

Reply to R.A. Ferrer et al and B.W. Corn.  33:4230-4231. 2015

Impact of tailored education on awareness of personal risk for therapy-related complications among childhood cancer survivors.  33:3887-3893. 2015

Recommendations for obesity clinical trials in cancer survivors: American Society of Clinical Oncology statement.  33:3961-3967. 2015

Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A center for international blood and marrow transplant research study.  33:3741-3749. 2015

Evaluation of the safety and benefit of phase I oncology trials for patients with primary CNS tumors.  33:3186-3192. 2015

Results of the exercise and nutrition to enhance recovery and good health for you (ENERGY) trial: A behavioral weight loss intervention in overweight or obese breast cancer survivors.  33:3169-3176. 2015

Trends toward declining aggressive care at end of life among older cancer patients in the Deep South 2015

Collaborative research in childhood cancer survivorship: The current landscape.  33:3055-3064. 2015

Late mortality after dexrazoxane treatment: A report from the Children's Oncology Group.  33:2639-2645. 2015

Reduction in late mortality among 5-year survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS)..  33:LBA2. 2015

Disparities in hospice use among patients with cancer in the Deep South 2015

Identifying sources of distress in patients with breast cancer 2015

An evaluation of systemic therapy beyond second-line therapy in patients with stage IV non-small cell lung cancer..  33:e19129-e19129. 2015

CELF4 variant and Anthracycline-related Cardiomyopathy (anth-card) – A COG Study (ALTE03N1)..  33:10066-10066. 2015

Gene expression profiling to improve prognostic stratification of men with advanced penile squamous cell cancer (PSCC) receiving first-line systemic therapy..  33:e15633-e15633. 2015

Identification of independent negative prognostic factors in stage IV non-small cell lung cancer..  33:e19133-e19133. 2015

Patient navigation as a model to increase minority participation in cancer clinical trials..  33:6559-6559. 2015

EMERGE: A randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB - Expressing breast cancer.  33:1609-1619. 2015

Fewer scans, better care.  33:1624. 2015

Long-term pulmonary function in survivors of childhood cancer.  33:1592-1600. 2015

Benefits of early versus delayed palliative care to informal family caregivers of patients with advanced cancer: Outcomes from the ENABLE III randomized controlled trial.  33:1446-1452. 2015

Early versus delayed initiation of concurrent palliative oncology care: Patient outcomes in the ENABLE III randomized controlled trial.  33:1438-1445. 2015

Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia.  33:1235-1242. 2015

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.  33:1252-1257. 2015

Benefits of Early versus Later Palliative Care to Informal Family Caregivers of Persons with Advanced Cancer: Outcomes from the ENABLE III Randomized Clinical Trial. 2015

Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: Results from children's oncology group study AALL07P4.  32:3874-3882. 2014

Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.  32:3840-3847. 2014

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.  32:3619-3625. 2014

American Society of Clinical Oncology position statement on obesity and cancer.  32:3568-3574. 2014

Guiding lay navigation using the distress thermometer..  32:195. 2014

Impact of care at NCI Comprehensive Cancer Centers (NCICCC) on cancer outcome: Results from a population-based study..  32:188. 2014

Comorbidity-age index: A clinical measure of biologic age before allogeneic hematopoietic cell transplantation.  32:3249-3256. 2014

Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.  32:2940-2950. 2014

Breast cancer after chest radiation therapy for childhood cancer.  32:2217-2223. 2014

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: Results of the US Leukemia intergroup trial E1905.  32:1242-1248. 2014

Cytogenetic prognostication within medulloblastoma subgroups.  32:886-896. 2014

Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: A report from the children's oncology group.  32:647-653. 2014

Immediate vs delayed initiation of concurrent palliative oncology care: Patient outcomes of the ENABLE III randomized controlled trial 2014

Epigenetics meets genetics in acute myeloid leukemia: Clinical impact of a novel seven-gene score.  32:548-556. 2014

Ototoxicity in children with high-risk neuroblastoma: Prevalence, risk factors, and concordance of grading scales - A report from the Children's Oncology Group.  32:527-534. 2014

Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: Analysis of transplantation timing and modality.  32:273-281. 2014

Comprehensive kinase profiling to classify clear cell (cc)-renal cell carcinoma (RCC)..  32:409-409. 2014

Integrated comprehensive high-throughput kinomics profiling and whole exome sequencing of penile squamous cell cancer (PSCC)..  32:383-383. 2014

Association between the prevalence of symptoms and health-related quality of life in adult survivors of childhood cancer: A report from the st jude lifetime cohort study.  31:4242-4251. 2013

Impact of care at NCI comprehensive cancer centers (NCICCC) on outcomes in children, adolescents, and young adults (AYA) with central nervous system tumors (CNSt)..  31:123. 2013

Storage, disposal, and utilization of opioids among cancer outpatients..  31:222-222. 2013

Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: A report from the children's oncology group.  31:3397-3402. 2013

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.  31:3212-3218. 2013

Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma.  31:3100-3109. 2013

Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.  31:2927-2935. 2013

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O(6)-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study..  31:LBA2009. 2013

Reply to K. Orendi et al.  31:2361-2362. 2013

Clinical role of micrornas in cytogenetically normal acute myeloid leukemia: MiR-155 Upregulation independently identifies high-risk patients.  31:2086-2093. 2013

To your health: How does the latest research on alcohol and breast cancer inform clinical practice?.  31:1917-1919. 2013

The potential impact of the Deep South Network for Cancer Control on cervical cancer mortality among black females in historically underserved areas of Alabama..  31:6559-6559. 2013

The role of Rac proteins in glioblastoma stem cells..  31:e13011-e13011. 2013

Patient benefit from salvage radiation for prostate cancer..  31:175. 2013

American society of clinical oncology statement: Achieving high-quality cancer survivorship care.  31:631-640. 2013

Extended neoadjuvant chemotherapy (CT) in borderline resectable pancreas cancer (BRPC): Is preoperative chemoradiation (CRT) essential?.  31:236-236. 2013

Role of biliary CEACAM6 as a biomarker for cholangiocarcinoma..  31:177-177. 2013

Quality of life among long-term survivors of non-Hodgkin lymphoma: A follow-up study.  31:272-279. 2013

A phase II, randomized, open label trial of preoperative letrozole versus letrozole (LET) in combination with bevacizumab (BEV) in post-menopausal women with newly diagnosed stage II/III breast cancer.  31:527-527. 2013

An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC) with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with metastatic triple negative breast cancer.  31. 2013

Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.  30:4515-4523. 2012

Yield of Screening for Long-Term Complications Using the Children's Oncology Group Long-Term Follow-Up Guidelines.  30:4401-4408. 2012

The effect of care at NCI comprehensive cancer centers on disparities in outcome in adolescents and young adults (AYAs) with cancer..  30:217. 2012

Failure to rescue as a source of variation in hospital mortality for ovarian cancer.  30:3976-3982. 2012

Troublesome symptoms in cancer survivors: Fatigue, insomnia, neuropathy, and pain.  30:3687-3696. 2012

Reply to C.D. Atkins.  30:3563-3564. 2012

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: Results from the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657.  30:3242-3249. 2012

Reply to M.C. Chamberlain et al.  30:3316-3317. 2012

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures.  30:3109-3118. 2012

Hyperfractionated or accelerated radiotherapy in lung cancer: An individual patient data meta-analysis.  30:2788-2797. 2012

Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: A report from the children's oncology group.  30:2545-2551. 2012

Reach out to enhance wellness home-based diet-exercise intervention promotes reproducible and sustainable long-term improvements in health behaviors, body weight, and physical functioning in older, overweight/obese cancer survivors.  30:2354-2361. 2012

New insights into the risk of breast cancer in childhood cancer survivors treated with chest radiation: A report from the Childhood Cancer Survivor Study (CCSS) and the Women's Environmental Cancer and Radiation Epidemiology (WECARE) Study..  30:CRA9513. 2012

Nonadherence to oral mercaptopurine and risk of relapse in hispanic and non-hispanic white children with acute lymphoblastic leukemia: A report from the Children's Oncology Group.  30:2094-2101. 2012

Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer.  30:2102-2111. 2012

Incidence and characterization of venous thromboembolic events (VTE) in patients with pancreatic cancer: Effect of timing of VTE on survival..  30:4037-4037. 2012

Anthracycline-related cardiomyopathy after childhood cancer: Role of polymorphisms in carbonyl reductase genes - A report from the Children's Oncology Group.  30:1415-1421. 2012

Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.  30:742-750. 2012

Reply to J. Lagro et al.  30:561-562. 2012

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.  30:362-371. 2012

Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases.  30:419-425. 2012

Hormone receptor expression and risk of recurrence in patients with high-risk endometrial carcinoma treated with chemotherapy.  30:e15502-e15502. 2012

Development and independent validation of a prognostic assay for stage ii colon cancer using formalin-fixed paraffin-embedded tissue.  29:4620-4626. 2011

Post-traumatic stress symptoms in long-term non-Hodgkin's lymphoma survivors: Does time heal?.  29:4526-4533. 2011

Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data..  29:4401-4409. 2011

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.  29:3877-3884. 2011

An update on the dosimetric analysis of concurrent radiation therapy and trastuzumab on early cardiac events..  29:121. 2011

SmgGDS splice variants: Potential novel targets for breast cancer therapeutics..  29:225-225. 2011

Treatment-related changes in neurobehavioral symptoms..  29:167. 2011

Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study.  29:3457-3465. 2011

Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: A report from the childhood cancer survivor study.  29:3056-3064. 2011

Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232..  29:3. 2011

Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324.  29:2312-2318. 2011

A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma..  29:2010. 2011

Long-term follow-up of dose-dense neoadjuvant chemotherapy in patients with stage II/III breast cancer..  29:e11048. 2011

Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with Radiation Therapy (RTOG 9003).  29:1326-1334. 2011

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: A cancer and leukemia group B study.  29:1373-1381. 2011

Efficacy and rectal toxicity of hypofractionated radiation therapy with daily image guidance..  29:85. 2011

Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: Primary analysis of Radiation Therapy Oncology Group study RTOG 0214.  29:272-278. 2011

Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: Neurocognitive and quality-of-life analysis.  29:279-286. 2011

Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and mll gene rearrangements: A report from the children's oncology group.  29:214-222. 2011

Racial and ethnic disparities in risk and survival in children with neuroblastoma: A children's oncology group study.  29:76-82. 2011

Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study.  28:5257-5264. 2010

Capacity to consent to research participation in adults with malignant glioma.  28:3844-3850. 2010

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study.  28:2348-2355. 2010

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.  28:1749-1755. 2010

Favorable Prognostic Impact of NPM1 Mutations in Older Patients with Cytogenetically Normal de Novo Acute Myeloid Leukemia and Associated Gene- And MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study.  28:596-604. 2010

Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.  28:549-555. 2010

Improved early event-free survival with imatinib in Philadelphia chromosome - Positive acute lymphoblastic leukemia: A Children's Oncology Group Study.  27:5175-5181. 2009

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.  27:5023-5030. 2009

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responses.  27:4754-4759. 2009

Predictive capacity of three comorbidity indices in estimating mortality after surgery for colon cancer.  27:4339-4345. 2009

Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study.  27:3198-3204. 2009

A phase I evaluation of intravenous (IV) (131)I-chlorotoxin delivery to solid peripheral and intracranial tumors..  27:e14507. 2009

A phase I evaluation of intravenous TM601 in recurrent glioblastoma: Use of perfusion MRI to monitor antiangiogenic effects..  27:2041. 2009

A phase I study of ABT 510 and concurrent temozolamide and radiotherapy for patients with newly diagnosed glioblastoma multiforme..  27:2023. 2009

A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients..  27:2536. 2009

Can primary recurrences in surgical stage I-II uterine papillary serous carcinoma (UPSC) patients be salvaged?.  27:e16503. 2009

Challenges for retrospective cohort studies: A profile of patients who refuse participation or are lost to follow-up..  27:6615. 2009

Current survival statistics for patients with newly diagnosed glioblastoma treated with radiation and temozolomide on research studies in the United States..  27:2003. 2009

Detection of Merkel cell polyomavirus in formalin-fixed, paraffin-embedded tissue of Merkel cell carcinoma and its correlation with prognosis..  27:6027. 2009

Differential survival after prostate cancer by race: Role of NCI-designated comprehensive cancer centers..  27:6520. 2009

Dosimetry study of a phase II multiple-dose intracavitary administration of (131)I-TM601 in adult patients with recurrent high-grade glioma..  27:e13006. 2009

Feasibility and phase I trial of tandutinib in patients with recurrent glioblastoma..  27:2039. 2009

In vitro chemoresponse assay results and population chemotherapy response rates in endometrial cancer..  27:5503. 2009

NABTT 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM)..  27:2001. 2009

NABTT-0702: A phase II study of R-(-)-gossypol (AT-101) in recurrent glioblastoma multiforme (GBM)..  27:2010. 2009

Prognostic significance of VDR, DKK-1, and DKK-4 expression in colorectal cancer..  27:e15047. 2009

Recommendation of adjuvant chemotherapy and trastuzumab in older adults with HER2-positive breast cancer: A survey of oncologists..  27:9547. 2009

Role of IκBα as a negative regulator of EGFR and a molecular determinant of prognosis in glioblastoma multiforme..  27:2028. 2009

Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results..  27:2042. 2009

Health behaviors influence cancer survival.  27:1930-1932. 2009

Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma.  27:791-798. 2009

Late congestive heart failure after hematopoietic cell transplantation.  26:5537-5543. 2008

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.  26:5610-5617. 2008

Reirradiation and concurrent chemotherapy after salvage surgery: Pay now or pay later.  26:5500-5501. 2008

Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis..  26:5380-5385. 2008

Role of age and health in treatment recommendations for older adults with breast cancer: The perspective of oncologists and primary care providers.  26:5386-5392. 2008

Remission after radiotherapy for a patient with chemotherapy-refractory HIV-associated primary effusion lymphoma.  26:5297-5299. 2008

Prognostic significance of, and gene and MicroRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: A cancer and leukemia group B study.  26:5078-5087. 2008

Phase II trial of sorafenib in advanced thyroid cancer.  26:4714-4719. 2008

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study.  26:4595-4602. 2008

Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.  26:2489-2496. 2008

Effect of TRA-8 anti-DR5 monoclonal antibody in combination with chemotherapy in an ex vivo human ovarian cancer model..  26:14695. 2008

Stage-specific survival differences associated with postoperative radiotherapy for gastrointestinal cancers.  26. 2008

Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.  26:897-906. 2008

Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - A report from the children's oncology group.  26:633-638. 2008

Move onward, press forward, and take a deep breath: Can lifestyle interventions improve the quality of life of women with breast cancer, and how can we be sure?.  25:4344-4345. 2007

Biology of interactions: Antiepidermal growth factor receptor agents.  25:4057-4065. 2007

High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study.  25:3337-3343. 2007

Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).  25:3124-3129. 2007

Main outcomes of the FRESH START trial: A sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors.  25:2709-2718. 2007

Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.  25:2191-2197. 2007

Lessons learned in the management of advanced pancreatic cancer.  25:1949-1952. 2007

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.  25:1651-1657. 2007

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators.  25:669-674. 2007

Interpreting the economic literature in oncology.  25:196-202. 2007

Clinical cancer advances 2006: Major research advances in cancer treatment, prevention, and screening - A report from the American Society of Clinical Oncology.  25:146-162. 2007

Significance of necrosis in grading of oligodendroglial neoplasms: A clinicopathologic and genetic study of newly diagnosed high-grade gliomas.  24:5419-5426. 2006

Promoting health and physical function among cancer survivors: Potential for prevention and questions that remain.  24:5125-5131. 2006

Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.  24:5025-5033. 2006

Disadvantage of men living alone participating in radiation therapy oncology group head and neck trials.  24:4177-4183. 2006

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B study.  24:3904-3911. 2006

Cancer survival: Time to get moving? Data accumulate suggesting a link between physical activity and cancer survival.  24:3517-3518. 2006

Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.  24:3644-3650. 2006

Lifestyle intervention development study to improve physical function in older adults with cancer: Outcomes from project LEAD.  24:3465-3473. 2006

Postoperative radiotherapy in non-small-cell lung cancer warrants further exploration in the era of adjuvant chemotherapy and conformal radiotherapy.  24:2978-2980. 2006

A novel low molecular weight inhibitor of focal adhesion kinase and insulin-like growth factor-1 receptor, TAE226, inhibits glioma growth..  24:11505. 2006

An IMRT technique to increase therapeutic ratio of breast irradiation in patients with early stage left breast cancer: Limiting second malignancies..  24:10791. 2006

Effects of depression on quality of life in Medicare beneficiaries with prostate cancer..  24:8510. 2006

Phase I trial of bortezomib in adults with recurrent malignant glioma..  24:1567. 2006

Phenotypic expression of Bax is a predictive marker of 5-fluorouracil treatment in colorectal cancer..  24:3605. 2006

Polymorphisms in candidate genes in patients with congestive heart failure (CHF) after childhood cancer: A Report from the Childhood Cancer Survivor Study (CCSS)..  24:9004. 2006

Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma.  24:2849-2857. 2006

Results of FRESH START: A randomized controlled trial to improve diet and exercise behaviors in breast and prostate cancer survivors..  24:8503. 2006

Results of FRESH START: A randomized controlled trial to improve diet and exercise behaviors in breast and prostate cancer survivors..  24:468S-468S. 2006

Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer..  24:10622. 2006

Safety and tolerance of multiple weekly intracavitary injections of 131I-chlorotoxin (TM-601): Preliminary results of a prospective clinical trial in patients with recurrent glioblastoma multiforme..  24:1555. 2006

Solid organ second malignant neoplasms among children diagnosed with malignant bone tumors treated on Children Cancer Study Group/Pediatric Oncology Group protocols after 1980..  24:9007. 2006

Tumor necrosis factor-α-induced protein 3 down-regulates nuclear factor-κB-mediated drug resistance in vitro and is a favorable clinical prognostic factor in human glioblastomas..  24:1508. 2006

Use of complementary and alternative medicine and spiritual practices among women with ovarian carcinoma in the southeastern United States..  24:15048. 2006

Visual complications in childhood cancer survivors: A Childhood Cancer Survivor Study report..  24:9006. 2006

Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.  24:2456-2464. 2006

Geriatric syndromes in elderly patients admitted to an oncology-acute care for elders unit.  24:2298-2303. 2006

Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer.  24:1982-1989. 2006

Tumor necrosis factor-α-induced protein 3 as a putative regulator of nuclear factor-κB-mediated resistance to O⁶-alkylating agents in human glioblastomas.  24:274-287. 2006

Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation Therapy Oncology Group Phase II Trial 99-14.  23:3008-3015. 2005

In reply [2].  23:9428. 2005

Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.  23:2004-2011. 2005

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: A cancer and leukemia group B study.  23:482-493. 2005

Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B study.  23:9234-9242. 2005

Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: Expression analysis of genes related to outcome.  23:8679-8687. 2005

Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non-small-cell lung cancer.  23:9089-9096. 2005

Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study.  23:5705-5717. 2005

Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy.  23:4399-4405. 2005

Riding the crest of the teachable moment: Promoting long-term health after the diagnosis of cancer.  23:5814-5830. 2005

Uncommon malignancies: Case 2. Gastric choriocarcinoma.  23:6251-6253. 2005

Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.  23:6699-6711. 2005

Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer.  23:6664-6673. 2005

Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer stage III and IV nasopharyngeal cancer of the endemic variety.  23:6730-6738. 2005

Feasibility of hand-assisted laparoscopic surgery (HALS) in gynecologic oncology patients..  23:5153. 2005

Results of Project LEAD (Leading the Way in Exercise and Diet) - A trial testing an intervention of telephone-counseling and mailed materials in improving physical functioning among older breast and prostate cancer survivors.  23:763S-763S. 2005

Results of Project LEAD (Leading the Way in Exercise and Diet) - A trial testing an intervention of telephone-counseling and mailed materials in improving physical functioning among older breast and prostate cancer survivors..  23:8138. 2005

TRAIL death receptor therapy for malignant glioma..  23:3187. 2005

TRAIL-mediated induction of apoptosis as a targeted therapy for prostate cancer..  23:3186. 2005

Utility of immunohistochemistry tissue array in the prediction of epithelial ovarian carcinoma response to therapy..  23:5033. 2005

Development of risk-based guidelines for pediatric cancer survivors: The Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline.  22:4979-4990. 2004

Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: Results from Cancer and Leukemia Group B study 8461.  22:2410-2418. 2004

Individualized patient dosing in phase I clinical trials: The role of Escalation with Overdose Control in PNU-214936.  22:602-609. 2004

Phase II trial of gefitinib in recurrent glioblastoma.  22:133-142. 2004

Preliminary results of Radiation Therapy Oncology Group 97-03: A randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.  22:2856-2864. 2004

Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461.  22:1087-1094. 2004

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.  22:1063-1070. 2004

Understanding cancer treatment and outcomes: The cancer care outcomes research and surveillance consortium.  22:2992-2996. 2004

Detection of disseminated breast cancer growth and treatment response using non-invasive bioluminescence imaging..  22:742. 2004

Feasibility study of liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked stage IIIC/IV ovarian cancer patients..  22:5044. 2004

Poor prognosis of taxane/platinum treated advanced stage ovarian cancer patients despite a negative second look laparotomy..  22:5083. 2004

High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: Report from the Late Effects Study Group.  21:4386-4394. 2003

Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.  21:4314-4321. 2003

Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133.  21:3512-3519. 2003

The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly.  21:3201-3206. 2003

The Minneapolis-Manchester quality of life instrument: Reliability and validity of the adolescent form.  20:4692-4698. 2002

Revision of the American Joint Committee on cancer staging system for breast cancer.  20:3628-3636. 2002

Nutrition and survival after the diagnosis of breast cancer: A review of the evidence.  20:3302-3316. 2002

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.  20:3262-3269. 2002

Adjuvant radiation therapy after complete resection of non-small-cell lung cancer [3] (multiple letters).  20:1427-1429. 2002

Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A pediatric oncology group trial.  20:426-433. 2002

Neuropsychologic impact of standard dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma 2002

Balancing the possible effectiveness of postoperative radiotherapy for non-small-cell lung cancer against the possible detriment of radiation-induced toxicity.  19:3905-3907. 2001

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.  19:3918-3928. 2001

Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system.  19:3622-3634. 2001

Is there an association between total-body irradiation and secondary acute myelogenous leukemia/myelodysplastic syndrome in patients with relapsed/refractory Hodgkin's disease treated with autologous stem-cell transplantation? [2] (multiple letters).  19:3585-3588. 2001

Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.  19:3234-3243. 2001

Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy.  19:2381-2389. 2001

Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: A cancer and leukemia group B study.  19:2482-2492. 2001

Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.  19:2171-2178. 2001

Solid cancers after bone marrow transplantation.  19:464-471. 2001

BR96-doxorubicin: Been there, done that! [1] (multiple letters).  18:4000. 2000

Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers..  18:47S-53S. 2000

Hormonal predictors of prostate cancer: A meta-analysis.  18:847-853. 2000

Multicenter phase II study of iodine-131 tositumomab for chemotherapy- relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.  18:1316-1323. 2000

Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors.  18:2282-2292. 2000

Massage therapy for patients undergoing autologous bone marrow transplant 1999

Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) Translocation.  17:191-196. 1999

Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.  17:3767-3775. 1999

Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma.  17:2681-2691. 1999

Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer.  17:478-484. 1999

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.  17:268-276. 1999

Consolidation therapy with antimetabolite-based therapy in standard- risk acute lymphocytic leukemia of childhood: A pediatric oncology group study.  16:2840-2847. 1998

Maximum-tolerated dose, toxicity, and efficacy of ¹³¹I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.  16:3246-3256. 1998

Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease.  16:818-829. 1998

Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: A pediatric oncology group study.  16:2854-2863. 1998

Second cancers after pediatric Hodgkin's disease [2] (multiple letters).  16:2570-2572. 1998

Assessment of genomic damage in colorectal cancer by DNA fingerprinting: Prognostic applications.  15:3230-3240. 1997

Association of local recurrence with subsequent survival in extremity soft tissue sarcoma.  15:646-652. 1997

Brain tumor-polyposis syndrome: Two genetic diseases?.  15:2744-2758. 1997

Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): Results from Cancer and Leukemia Group B 8461.  15:466-475. 1997

Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: A phase I study.  15:901-907. 1997

Phase II trial of docetaxel in non-Hodgkin's lymphomas: A study of the cancer and leukemia group B.  15:3275-3279. 1997

Prognostic factors associated with long-term survival for retroperitoneal sarcoma: Implications for management.  15:2832-2839. 1997

Secondary cytogenetic changes in acute promyelocytic leukemia - Prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: A Cancer and Leukemia Group B study.  15:1786-1795. 1997

Chemotherapy followed by accelerated fractionated radiation for larynx preservation in patients with advanced laryngeal cancer.  14:2322-2330. 1996

Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: A Pediatric Oncology Group study.  14:1252-1261. 1996

Prognostic significance of a positive microscopic margin in high-risk extremity soft tissue sarcoma: Implications for management.  14:473-478. 1996

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.  14:18-24. 1996

Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.  13:1384-1390. 1995

Effect of a National Cancer Institute Clinical Alert on breast cancer practice patterns.  12:1783-1788. 1994

Limited-stage small-cell lung cancer: Patterns of intrathoracic recurrence and the implications for thoracic radiotherapy.  12:496-502. 1994

Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.  12:1890-1901. 1994

Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: A randomized trial of the southeastern cancer study group.  11:1223-1229. 1993

Immunophenotypes and karyotypes of leukemic cells in children with down syndrome and acute lymphoblastic leukemia.  11:1361-1367. 1993

Stage III neuroblastoma over 1 year of age at diagnosis: Improved survival with intensive multimodality therapy including multiple alkylating agents.  11:84-90. 1993

Why women gain weight with adjuvant chemotherapy for breast cancer.  11:1418-1429. 1993

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group study.  10:1103-1111. 1992

Ploidy of lymphoblasts is the strongest predictor of treatment outcome in b-progenitor cell acute lymphoblastic leukemia of childhood: A pediatric oncology group study.  10:606-613. 1992

Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: A Pediatric Oncology Group randomized phase II study.  10:249-256. 1992

Corynebacterium parvum versus bacille calmette-guérin adjuvant immunotherapy of stage II malignant melanoma.  9:1151-1156. 1991

Prognostic significance of CD34 expression in childhood B-precursor acute lymphocytic leukemia: A pediatric oncology group study.  8:1389-1398. 1990

Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: A Southeastern Cancer Study Group trial.  8:886-891. 1990

Phase II treatment of medulloblastoma and pineoblastoma with melphalan: Clinical therapy based on experimental models of human medulloblastoma.  7:904-911. 1989

A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer.  6:1397-1400. 1988

Clinical use of a standard kit-preparation of radiolabeled monoclonal antibody 96.5 in the diagnostic imaging of metastatic melanoma.  6:1059-1065. 1988

Consolidation and maintenance therapy in multiple myeloma: Randomized comparison of a new approach to therapy after initial response to treatment.  4:888-899. 1986

Ewing's sarcoma in bones of the hands and feet: A clinicopathologic study and review of the literature.  3:686-697. 1985

Phase III study of BCOP v CHOP in unfavorable categories of malignant lymphoma: A Southeastern Cancer Study Group Trial.  3:1188-1195. 1985

Randomized phase III comparison of three doxorubicin-based chemotherapy regimens in advanced non-small cell lung cancer: A Southeastern Cancer Study Group trial.  2:391-395. 1984

Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a 'cycle active' non-cross-resistant combination in women with visceral metastatic breast cancer: A Southeastern Cancer Study Group project.  2:643-651. 1984

A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma..  1:720-726. 1983